Womens Health Investment Outlook 2026

Point of caution for investors –Regulatory scrutiny: Premium diagnostics and concierge-style services remain under regulatory scrutiny and often lack robust clinical validation. 3.6 Wearable devices and platforms for women’s metabolic health Current activity Wearable devices and digital platforms for metabolic health represent one of healthcare’s most dynamic areas, driven by the rapid rise of glucose- like peptide-1 (GLP-1) therapies and demand for continuous, data-driven management of weight and metabolic disorders. The total addressable market was estimated at $11 billion globally in 2025, with North America accounting for $4 billion. The category includes 28 identified companies that have raised approximately $164 million across more than 40 financings in the past five years. Private investment accounted for 90% of deal activity. In the US, although less than 1% of NIH’s 2024 research budget (approximately $1.2 billion) was allocated to diabetes research, mobile health (mHealth) and/or remote intervention trials have opened new channels for wearable-enabled metabolic health research.102,103 Additionally, the type 1 diabetes Special Program ($160 million per year) has accelerated continuous glucose monitoring (CGM) technology development.104 Payer coverage for CGM devices is expanding and AI-enabled personalization of reproductive and metabolic data is expected to drive accelerated adoption and monetization. Investment events, wearable devices and platforms for women’s metabolic health FIGURE 14 Source: Pitchbook, CapIQ, Crunchbase, Boston Consulting GroupPre-seed/seed Early-stage VC Later -stage VC Other Private funding $ UndisclosedPrivate investment funding deals for wearable devices and platforms for women’s metabolic health 63% of deals disclosed funding 0 5 0 15 1 0 0 500 1 676 92811 7 4Deal Total funding ($M) 2021 2022 2023 2024 Women’s Health Investment Outlook 29